Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

NCT01822613 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: LJM716
DRUG: BYL719
DRUG: Paclitaxel
DRUG: Docetaxel
DRUG: Irinotecan

Sponsor

Novartis Pharmaceuticals